Informazioni sul prodotto
Nome:
1-nitrotridec-1-ene
Sinonimi:
- [u'3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate', u'arformoterol', u'BD 40A', u'eformoterol', u'Foradil', u'formoterol', u'formoterol fumarate', u'formoterol fumarate, ((R*,R*)-(+-))-isomer', u'formoterol, ((R*,R*)-(+-))-isomer', u'Oxis', u'Arformoterol', u'formoterol', u'(R,R)-Formoterol', u'67346-49-0', u'73573-87-2', u'(-)-Formoterol', u'Brovana', u'UNII-F91H02EBWT', u'Foradil', u'Atimos', u'Oxis', u'Arformoterol (INN)', u'Arformoterol [INN]', u'eformoterol', u'Arformoterol tartrate', u'CHEMBL1363', u'F91H02EBWT', u'Formoterolum', u'CHEBI:408174', u'N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide', u'Formoterolum [INN-Latin]', u'N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide', u'Formoterol [USAN:INN:BAN]', u'HSDB 7287', u'FORMOTEROL FUMARATE', u'Innovair', u'Fluir', u'Racemic formoterol', u'(+-)-Formoterol', u'YM-08316', u'AC1MJ0T4', u'SCHEMBL4247', u'GTPL7479', u'cid_9912089', u'HY-B0010A', u'BPZSYCZIITTYBL-YJYMSZOUSA-N', u"(+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide", u'ZINC2599970', u'BDBM50151720', u'MFCD05662345', u'AKOS015969668', u'API0009091', u'CS-1413', u'DB01274', u'SB17482', u'AJ-44036', u'AN-38345', u'N-{2-hydroxy-5-[(1R)-1-hydroxy-2-({(1R)-1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)ethyl]phenyl}formamide', u'SC-94426', u'X5000', u'(-)-Formoterol;Arformoterol;(R,R)-Formoterol', u'73F872', u'D07463', u'W-5127', u'UNII-5ZZ84GCW8B component BPZSYCZIITTYBL-YJYMSZOUSA-N', u'Foradil/Foradile (Schering-Plough in the U.S., Novartis rest of world), Oxeze/Oxis (AstraZeneca), Atock (Astellas), Atimos/Atimos Modulite (Chiesi), and Perforomist (Dey)', u'Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-', u'Formamide, N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, (R-(R*,R*))-', u'H98', u'N-(2-Hydroxy-5-((R)-1-hydroxy-2-(((R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)phenyl)formamide', u'N-(2-hydroxy-5-((R)-1-hydroxy-2-((R)-1-(4-methoxyphenyl)propan-2-ylamino)ethyl)phenyl)formamide', u'N-(2-Hydroxy-5-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1-methyl-ethylamino]-ethyl}-phenyl)-formamide', u'N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methyl-ethyl]amino]ethyl]phenyl]formamide', u'rel-N-(2-Hydroxy-5-((R)-1-hydroxy-2-(((R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)phenyl)formamide', u'Perforomist', u'Symbicort', u'Formoterol Base', u'Flutiform (TN)', u'Symbicort (TN)', u'Brovana (TN)', u'Formoterol/budesonide', u'UNII-5ZZ84GCW8B', u'Formoterol [INN:BAN]', u'Formoterol [USAN:INN]', u'D0D1DI', u'D0E5FY', u'D0P2AG', u'5ZZ84GCW8B', u'BD 40A', u'CHEMBL605993', u'Formoterol/fluticasone propionate', u'C19H24N2O4', u'CGP-25827A', u'C19-H24-N2-O4', u'CID3083544', u'CS-O-00859', u'formoterol, ((R*,R*)-(+-))-isomer', u'2256B', u'formoterol fumarate, ((R*,R*)-(+-))-isomer', u'D000068759']
- rel-N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide
- Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*,R*)-(±)-
- Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, rel-
- Formoterol
- Eformoterol
Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Indagoo
Conservazione lunga:
Note:
Proprietà chimiche
Peso molecolare:
227.3431
Formula:
C13H25NO2
Purezza:
98%
Colore/Forma:
Solid
InChI:
InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1
InChI key:
BPZSYCZIITTYBL-YJYMSZOUSA-N
MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:
